1. Home
  2. MDWD vs GAUZ Comparison

MDWD vs GAUZ Comparison

Compare MDWD & GAUZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • GAUZ
  • Stock Information
  • Founded
  • MDWD 2000
  • GAUZ 2009
  • Country
  • MDWD Israel
  • GAUZ Israel
  • Employees
  • MDWD N/A
  • GAUZ N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • GAUZ Industrial Machinery/Components
  • Sector
  • MDWD Health Care
  • GAUZ Miscellaneous
  • Exchange
  • MDWD Nasdaq
  • GAUZ Nasdaq
  • Market Cap
  • MDWD 230.6M
  • GAUZ 180.1M
  • IPO Year
  • MDWD 2014
  • GAUZ 2024
  • Fundamental
  • Price
  • MDWD $19.12
  • GAUZ $7.82
  • Analyst Decision
  • MDWD Strong Buy
  • GAUZ Strong Buy
  • Analyst Count
  • MDWD 2
  • GAUZ 4
  • Target Price
  • MDWD $35.00
  • GAUZ $15.50
  • AVG Volume (30 Days)
  • MDWD 48.5K
  • GAUZ 28.0K
  • Earning Date
  • MDWD 08-13-2025
  • GAUZ 08-07-2025
  • Dividend Yield
  • MDWD N/A
  • GAUZ N/A
  • EPS Growth
  • MDWD N/A
  • GAUZ N/A
  • EPS
  • MDWD N/A
  • GAUZ N/A
  • Revenue
  • MDWD $19,213,000.00
  • GAUZ $101,165,000.00
  • Revenue This Year
  • MDWD $20.80
  • GAUZ $28.49
  • Revenue Next Year
  • MDWD $26.92
  • GAUZ $47.77
  • P/E Ratio
  • MDWD N/A
  • GAUZ N/A
  • Revenue Growth
  • MDWD N/A
  • GAUZ 18.63
  • 52 Week Low
  • MDWD $14.14
  • GAUZ $6.78
  • 52 Week High
  • MDWD $24.00
  • GAUZ $13.00
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 40.24
  • GAUZ N/A
  • Support Level
  • MDWD $19.11
  • GAUZ N/A
  • Resistance Level
  • MDWD $19.87
  • GAUZ N/A
  • Average True Range (ATR)
  • MDWD 0.63
  • GAUZ 0.00
  • MACD
  • MDWD -0.17
  • GAUZ 0.00
  • Stochastic Oscillator
  • MDWD 25.31
  • GAUZ 0.00

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About GAUZ Gauzy Ltd. Ordinary Shares

Gauzy Ltd is a fully integrated light and vision control company. Its products include suspended particle device and liquid crystal materials for smart glass applications and AI-powered driver assistance systems, or ADAS, solutions including camera monitoring systems. The company's operating segments are Architecture, Automotive, Safety tech, and Aeronautics. Maximum revenue is generated from its Safety tech segment, which focuses on sales of driver assistance systems for buses, coaches, recreational vehicles, and specific vehicles, such as camera and motion sensor systems, smart mirrors, and safety doors. Geographically, it derives maximum revenue from other European countries (excluding France), followed by the United States, France, Asia, Israel, and other regions.

Share on Social Networks: